GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2006

Merck Obtains Rights to Ambrilia’s HIV/AIDS Protease Inhibitor Program

  • Merck was granted worldwide rights to Ambrilia’s HIV/AIDS protease inhibitor (PI) program, according to an exclusive licensing agreement between the two companies.

    Under the terms of this agreement, Merck gained the rights to Ambrilia’s lead compound, PPL-100, which has completed a Phase I single-dose pharmacokinetic study and is currently in a Phase I repeat-dose pharmacokinetic study.

    In return, Ambrilia receives an upfront licensing fee of $17 million on signing and is eligible for cash payments totaling up to $215 million upon successful completion of development, clinical, regulatory, and sales milestones, as well as royalties on all future product sales.

    The first milestone payments of $3 million will be based on the successful completion of a Phase I repeat-dose pharmacokinetic study, the results of which are expected in late November. Once this Phase I study is completed, Merck will assume all subsequent development costs related to PPL-100.

    Ambrilia also stands to receive additional milestone-based cash payments and royalties on the future development and commercialization of each back-up compound and/or related compounds developed by Merck, which fall within the scope of the Ambrilia PI program.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?